Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.

Journal of molecular endocrinology - 1 Aug 2015

Rodríguez-Sanz M, García-Giralt N, Prieto-Alhambra D, Servitja S, Balcells S, Pecorelli R, Díez-Pérez A, Grinberg D, Tusquets I, Nogués X

Abstract excerpt

Aromatase inhibitors (AIs) used as adjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer cause diverse musculoskeletal side effects that include bone loss and its associated fracture. About half of the 391 patients treated with AIs in the Barcelona-Aromatase induced bone loss in early breast cancer cohort suffered a significant bone loss at lumbar spine (LS) and/or femoral neck...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase Inhibitors
Share to Bone and Bones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Density

Share to Cholesterol Side-Chain Cleavage Enzyme

Share to Estrogens

Share to Osteoblasts

Share to Osteoporosis, Postmenopausal

Share to Vitamin D

Source

Identifiers

PMID: 26108486
DOI: 10.1530/JME-15-0079

Genes

DHCR7
ESR1
VDR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.PMID 26108486Read ↗

CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up.Semantic proximity Read ↗

Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.Semantic proximity Read ↗

Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.Semantic proximity Read ↗

Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.Semantic proximity Read ↗

Significant association between common polymorphisms in the aromatase gene CYP19A1 and bone mineral density in postmenopausal women.Semantic proximity Read ↗

Bone Disease Associated with Inactivating Aromatase Mutations and its Management.Semantic proximity Read ↗

Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density.Semantic proximity Read ↗

A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women.Semantic proximity Read ↗

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.Semantic proximity Read ↗

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.Semantic proximity Read ↗

CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.Semantic proximity Read ↗

Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.